This database contains 136 studies, archived under the term: "Carer Burden (instruments measuring burden)"
Click here to filter this large number of results.
Does a family meetings intervention prevent depression and anxiety in family caregivers of dementia patients? A randomized trial
Joling, Karlijn J,
van Marwijk, Harm W.J.,
Smit, Filip,
van der Horst, Henriëtte E,
Scheltens, Philip,
van de Ven, Peter M.,
Mittelman, Mary S.,
van Hout, Hein P.J.
Background: Family caregivers of dementia patients are at increased risk of developing depression or anxiety. A multi-component program designed to mobilize support of family networks demonstrated effectiveness in decreasing depressive symptoms in caregivers. However, the impact of an intervention consisting solely of family meetings on depression and anxiety has not yet been evaluated. This study […]
Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomized clinical trial
Jansen, Aaltje P.D.,
van Hout, Hein P.J.,
Nijpels, Giel,
Rijmen, Frank,
Dröes, Rose-Marie,
Pot, Anne-Margriet,
Schellevis, François G.,
Stalman, Wim A.B.,
van Marwijk, Harm W.J.
Background: It is believed that timely recognition and diagnosis of dementia is a pre-condition for improving care for both older adults with dementia and their informal caregivers. However, diagnosing dementia often occurs late in the disease. This means that a significant number of patients with early symptoms of dementia and their informal caregivers may lack […]
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for […]
Influence of regular exercise on subjective sense of burden and physical symptoms in community-dwelling caregivers of dementia patients: a randomized controlled trial
Hirano, Akemi,
Suzuki, Yusuke,
Kuzuya, Masafumi,
Onishi, Joji,
Ban, Nobutaro,
Umegaki, Hiroyuki
With an aim to improve quality of life in caregivers of dementia patients, we examined the effect of regular exercise on caregivers’ sense of burden and their physical symptoms. Participants were 31 elderly caregivers living with older patients diagnosed with Alzheimer’s-type dementia. They were randomly assigned to either the intervention group, who were prescribed regular […]
Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial
Haïk, Stéphane,
Marcon, Gabriella,
Mallet, Alain,
Tettamanti, Mauro,
Welaratne, Arlette,
Giaccone, Giorgio,
Azimi, Shohreh,
Pietrini, Vladimiro,
Fabreguettes, Jean-Roch,
Imperiale, Daniele,
Cesaro, Pierre,
Buffa, Carlo,
Aucan, Christophe,
Lucca, Ugo,
Peckeu, Laurène,
Suardi, Silvia,
Tranchant, Christine,
Zerr, Inga,
Houillier, Caroline,
Redaelli, Veronica,
Vespignani, Hervé,
Campanella, Angela,
Sellal, François,
Krasnianski, Anna,
Seilhean, Danielle,
Heinemann, Uta,
Sedel, Frédéric,
Canovi, Mara,
Gobbi, Marco,
Di Fede, Giuseppe,
Laplanche, Jean-Louis,
Pocchiari, Maurizio,
Salmona, Mario,
Forloni, Gianluigi,
Brandel, Jean-Philippe,
Tagliavini, Fabrizio
Background: Creutzfeldt-Jakob disease (CJD) is a fatal, untreatable prion encephalopathy. Previous studies showed that doxycycline is effective in in-vitro and in-vivo models of disease, and patients with CJD who received compassionate treatment with doxycycline showed increased survival time compared with historical series. We therefore did a randomised, double-blind study of doxycycline versus placebo in CJD.; […]
Telephone-based, cognitive-behavioral therapy for African American dementia caregivers with depression: initial findings
Glueckauf, Robert L.,
Davis, W. Shuford,
Willis, Floyd,
Sharma, Dinesh,
Gustafson, David J.,
Hayes, Jocelyn,
Stutzman, Mary,
Proctor, James,
Kazmer, Michelle M.,
Murray, Leticia,
Shipman, Judith,
McIntyre, Vera,
Wesley, Lonnie,
Schettini, Gabriel,
Xu, Jian,
Parfitt, Francine,
Graff-Radford, Neill,
Baxter, Cynthia,
Burnett, Kathleen,
Noël, La Tonya,
Haire, Kambria,
Springer, Jane
Objectives: Discuss initial findings of a randomized clinical trial comparing the effects of telephone-based and face-to-face (f-to-f) cognitive-behavioral therapy (CBT) on changes in caregiver (CG) burden, assistance support, depression, and health status for African American (AA) CGs with depression.; Design: Pilot study using a prepost, two-group design with 14 enrolled and randomized participants.; Measures: Subjective […]
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease
Geschwind, M. D.,
Kuo, A. L.,
Wong, K. S.,
Haman, A.,
Devereux, G.,
Raudabaugh, B. J.,
Johnson, D. Y.,
Torres-Chae, C. C.,
Finley, R.,
Garcia, P.,
Thai, J. N.,
Cheng, H. Q.,
Neuhaus, J. M.,
Forner, S. A.,
Duncan, J. L.,
Possin, K. L.,
DeArmond, S. J.,
Prusiner, S. B.,
Miller, B. L.
Objective: To determine whether oral quinacrine increases survival in sporadic Creutzfeldt-Jakob disease (sCJD).; Methods: This NIH/National Institute on Aging-funded, double-blinded, placebo-controlled, stratified randomization treatment trial was conducted at the University of California, San Francisco from February 2005 through May 2009 (ClinicalTrials.gov, NCT00183092). Subjects were randomized (50:50) to quinacrine (300 mg daily) or placebo with inpatient […]